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Abstract
Background We aimed to validate Decipher to predict adverse pathology (AP) at radical prostatectomy (RP) in men with
National Comprehensive Cancer Network (NCCN) favorable-intermediate risk (F-IR) prostate cancer (PCa), and to better
select F-IR candidates for active surveillance (AS).
Methods In all, 647 patients diagnosed with NCCN very low/low risk (VL/LR) or F-IR prostate cancer were identiﬁed from
a multi-institutional PCa biopsy database; all underwent RP with complete postoperative clinicopathological information and
Decipher genomic risk scores. The performance of all risk assessment tools was evaluated using logistic regression model
for the endpoint of AP, deﬁned as grade group 3−5, pT3b or higher, or lymph node invasion.
Results The median age was 61 years (interquartile range 56–66) for 220 patients with NCCN F-IR disease, 53% classiﬁed
as low-risk by Cancer of the Prostate Risk Assessment (CAPRA 0−2) and 47% as intermediate-risk (CAPRA 3−5).
Decipher classiﬁed 79%, 13% and 8% of men as low-, intermediate- and high-risk with 13%, 10%, and 41% rate of AP,
respectively. Decipher was an independent predictor of AP with an odds ratio of 1.34 per 0.1 unit increased (p value =
0.002) and remained signiﬁcant when adjusting by CAPRA. Notably, F-IR with Decipher low or intermediate score did not
associate with signiﬁcantly higher odds of AP compared to VL/LR.
Conclusions NCCN risk groups, including F-IR, are highly heterogeneous and should be replaced with multivariable riskstratiﬁcation. In particular, incorporating Decipher may be useful for safely expanding the use of AS in this patient
population.

Introduction
Men diagnosed with what has classically been termed
“intermediate-risk” prostate cancer (PCa)—based on Gleason score 7, prostate-speciﬁc antigen (PSA) 10−20 ng/mL,
and clinical stage T2b or 2c disease—have highly variable
clinical behavior and prognosis and are considered a broad,
heterogeneous cohort for whom management recommendations cannot be standardized. The literature provides
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strong evidence that not all Gleason sums of 7 have equal
potential for progression. Men with a post radical prostatectomy (RP) Gleason 4 + 3 are more likely to develop
metastasis and die from PCa than patients with a Gleason
3 + 4 [1], and outcomes may vary further based on the
quantiﬁed predominance of pattern 4 disease [2, 3]. As a
consequence, contemporary Gleason grading has explicitly
assigned score 4 + 3 to a higher grade group (grade group 3,
GG3) than Gleason 3 + 4 (GG2) to address these levels of
risk [4]. Clinical T staging, meanwhile, has been shown
frequently inaccurate, and less important than better markers of tumor volume, such as extent of biopsy core
involvement [5].
The National Comprehensive Cancer Network (NCCN)
now separates men with intermediate-risk PCa into favorable and unfavorable subgroups in their guidelines [6, 7].
Favorable-intermediate risk (F-IR) tumors are deﬁned as
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GG1 or 2 tumors and no more than one NCCN
intermediate-risk factor (PSA 10−20 ng/mL, cT2b/c, or
GG2) and percentage of positive biopsy cores <50%. The
latter parameter was an arbitrary addition that makes clinical
sense but has never been validated to be an optimal
threshold, and in fact no other NCCN stratum uses percent
of cores involved. Studies have shown that men with F-IR
PCa have similar survival outcomes compared to low-risk
(LR) PCa patients, suggesting that some of these men may
be appropriate candidates for active surveillance (AS) [8].
Conversely, patients with unfavorable intermediate-risk
features demonstrate prostate cancer-speciﬁc and all-cause
mortality rates similar to men with high-risk PCa [9].
Unsurprisingly, recent study groups have demonstrated that
NCCN F-IR tumors have signiﬁcantly worse odds of
adverse pathology (AP) as compared to NCCN very low
(VL) and LR tumors and these men had a small but measurable decrease in overall survival [10, 11]. Therefore, the
suitability of men with F-IR tumors for AS remains
controversial.
Genomic classiﬁers (GC) were introduced into clinical
practice to improve risk-stratiﬁcation and to help guide
treatment decisions for men with PCa. Among them,
Decipher, which uses a whole-transcriptome microarray
assay, represents the most intensively studied GC [12]. It
generates a score ranging from 0 to 1, with higher values
indicating an increased probability for both AP and downstream oncologic outcomes. Utilization of molecular proﬁling with Decipher GC can result in improved
identiﬁcation of patients qualifying for AS by identifying
the subset of histologically LR PCa at diagnosis with
molecular characteristics conﬁrming indolent disease [13].
In this study, we aimed to validate the Decipher GC to
predict adverse pathology after RP in men with NCCN F-IR
prostate cancer. Further, we investigated whether combining Decipher with a multivariable clinical risk-stratiﬁcation
tool can substratify AP risk, identifying which men with
F-IR tumors may safely undergo AS.

Materials and methods
Study cohort
A multi-institutional PCa biopsy dataset was selected from
the Genomic Resource Information Database (GRID,
NCT02609269) consisting of 647 patients diagnosed with
NCCN VL/LR or F-IR risk from 1990 to 2016 whose
biopsies have undergone the Decipher testing and who
received RP as ﬁrst treatment. NCCN VL/LR was deﬁned
as follows: cT2a or lower, GG1, and PSA <10 ng/mL;
NCCN F-IR was deﬁned as GG1 or 2 and no more than one
of the NCCN intermediate-risk factor (PSA 10−20 ng/mL,
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cT2b/c or GG2) and <50% biopsy cores positive. Pathologic endpoints were abstracted from surgical pathology
reports. The research protocol was approved by institutional
review boards of the participating institutions (University of
California, San Francisco; University of Calgary; Johns
Hopkins University; Cedars-Sinai; Cleveland Clinic; Spectrum Health; Thomas Jefferson University; MD Anderson
Cancer Center).
Specimen collection and sample processing were conducted as described previously [13, 14]. The prostate needle
biopsy core with highest grade and percentage of core
involved with tumor was sampled for the Decipher assay, a
CAP/CLIA clinical-grade whole-transcriptome assay. GC
scores were generated based on a previously locked and
validated signature (GenomeDx, San Diego, CA, USA), for
all specimens [15].

Statistical analysis
The primary objective was to evaluate Decipher’s prognostic
ability to predict AP (deﬁned as GG 3−5, pT3b or higher, or
lymph node invasion (LNI) [14]) at RP within the NCCN
F-IR group while accounting for clinical risk using the linear,
extensively validated Cancer of the Prostate Risk Assessment
(CAPRA [16]) score. In addition to this deﬁnition of AP, we
also evaluated two alternatives: (1) GG 3−5 as an isolated
endpoint, and (2) expanding the deﬁnition of adverse
pathology to include extraprostatic extension (i.e., GG 3−5,
≥pT3a, or LNI (AP-II)). Further, we explored the possibility
for Decipher to substratify AP risk in the combined dataset of
VL/LR and F-IR patients. Descriptive statistics were provided with medians and ranges reported for continuous
variables and frequencies and proportions for categorical
variables. Previously determined cut points were used where
required for Decipher and CAPRA: (a) Decipher, 0.45 and
0.60 categorized the scores into low-, intermediate- and highrisk groups, respectively [17]; (b) CAPRA scores 0−2, 3−5,
6−10 were grouped as low, intermediate, and high, respectively [16]. In the NCCN + Decipher model, NCCN VL/LR
served as the reference group and NCCN F-IR was categorized into Decipher low, intermediate or high.
The performance of each risk assessment tool (e.g.,
Decipher, CAPRA) was evaluated using multivariable
penalized logistic regression modeling with Firth’s method
(to account for small event size) [18]. Area under the
receiver operating characteristic curves (AUCs) were generated for each model. AUC and its bootstrapped 95%
conﬁdence interval were constructed by 1000 resamples and
optimism adjustment was applied to multivariable models
[19]. Sensitivity analysis of the primary result was performed adjusting institution as a covariate.
All statistical tests were two-sided with p values less than
0.05 being considered as statistically signiﬁcant. No sample
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size determination was performed prior to retrieving eligible
patients from GRID. Analyses were performed in R, version
3.3.1 (R Foundation for Statistical Computing, Vienna,
Austria).

Results
Patient characteristics in the NCCN F-IR cohort
Decipher Biopsy was examined initially for its ability to
predict AP post-RP in 220 men with NCCN F-IR disease
(Table 1). The median age and PSA at diagnosis was
61 years (interquartile range (IQR) 56–66) and 5.9 ng/mL
(IQR 4.6–9.3), respectively. Two-thirds of patients were
diagnosed with cT1 and 62% had biopsy GG2 disease. All
but two men (who underwent targeted biopsy only) received
at least a standard 10 core template biopsy. The CAPRA
presurgical clinical risk model classiﬁed 53% as low-risk
(CAPRA 0−2) and 47% as intermediate-risk (CAPRA 3−4)
(Fig. 1a); a large majority of the F-IR patients were CAPRA
2 or 3. The Decipher GC risk model classiﬁed 79% (GC <
0.45), 13% (GC 0.45-0.6) and 8% (GC > 0.6) as low-,
intermediate- and high-risk, respectively (Fig. 1b). The
median time from biopsy to RP was 3 months (IQR 2.4–3).
After surgery, 74% had pathological stage pT2, 24% pT3a,
3% pT3b and 18% had positive surgical margins. Lymph
node involvement was not observed in any patient.
Upgrading from biopsy GG1 to any RP higher GG was
observed in 61%, of which only 14% were upgraded to GG3
or greater. Similarly, GG2 upgrading to GG3 or greater was
observed in 15% of tumors. Overall 15% had AP at RP, 15%
GG 3−5 only and 33% AP-II. Rate of biochemical recurrence at 3 years was 4% with a median follow-up of 2.8 years
(IQR: 1.3–5.7).

Comparison of Decipher and CAPRA for predicting
AP
Biopsy Decipher distribution was signiﬁcantly higher
among men with AP at RP (0.38, IQR 0.25–0.49) as
compared to those without (0.30, IQR 0.18−0.40, Wilcoxon rank sum test p value = 0.016). In univariable analysis (Table 2), the odds ratio (OR) of continuous CAPRA
score was 1.6 per 1 unit increased (95% CI 1.0−2.7) and for
continuous Decipher score OR was 1.3 per 0.1 unit
increased (95% CI 1.1−1.6). Decipher high-risk, but not
intermediate-risk, predicted AP with OR of 4.6 (95% CI
1.6−12.9) compared to low-risk groups. In multivariable
analysis, Decipher remained a signiﬁcant predictor. CAPRA
had an AUC of 0.60 (95% CI 0.51–0.70) and adding
Decipher increased the AUC to 0.65 (95% CI 0.57–0.71)
after optimism adjustment. Similar results were observed
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Table 1 Patient characteristics of F-IR cohort (n = 220) and VL/LR
and F-IR cohort (n = 647)
Variables

F-IR only

VL/LR and F-IR

No. patients, n (%)

220 (25)

647 (75)

Age
Median (Q1, Q3)

61 (56−66)

60 (55−65)

Race, n (%)
African American

11 (5)

27 (4)

Caucasian
Other

138 (63)
20 (9)

383 (59)
64 (10)

Unknown

51 (23)

173 (27)

Biopsy stage, n (%)
cT1
cT2
Biopsy grade group, n (%)
Grade group 1
Grade group 2

147 (67)

474 (73)

73 (33)

173 (27)

83 (38)
137 (62)

510 (79)
137 (21)

% positive biopsy cores
Median (Q1, Q3)

23.5 (14.3, 33.3)

PSA
Median (Q1, Q3)

5.86 (4.6, 9.29)

NCCN, n (%)
F-IR

220 (100)

VL/LR
CAPRA, n (%)

25 (15.4, 35.7)
5.47 (4.22, 7)
220 (34)
427 (66)

0
1

2 (1)
22 (10)

25 (4)
209 (32)

2
3

93 (42)
86 (39)

271 (42)
120 (19)

4
Unavailable

17 (8)

17 (3)
5 (1)

3 (2.37, 3)

3 (2.73, 3)

Time from biopsy to RP (month)
Median (Q1, Q3)
RP stage, n (%)
pT2c or less
pT3a
pT3b
RP grade group, n (%)
Grade group 1

162 (74)

492 (76)

52 (24)
6 (3)

141 (22)
14 (2)

56 (25)

273 (42)

Grade group 2
Grade group 3

132 (60)
27 (12)

309 (48)
52 (8)

Grade group 4
Grade group 5

4 (2)
1 (<1)

9 (1)
4 (1)

180 (82)
40 (18)

531 (82)
116 (18)

220 (100)

644 (99.5)

Positive surgical margins, n (%)
Absent
Present
Lymph node invasion, n (%)
Absent

Present
BCR follow-up (year) for censored patients
Median (Q1, Q3)

2.79 (1.33, 5.72)

3 (0.5)
3.49 (1.47, 6.8)

F-IR NCCN favorable-intermediate risk, VL/LR NCCN very low/low
risk, PSA prostate-speciﬁc antigen, NCCN National Comprehensive
Cancer Network, CAPRA Cancer of the Prostate Risk Assessment, RP
radical prostatectomy, BCR biochemical recurrence

for two alternative deﬁnitions of AP- GG 3-5 and AP-II
(Supp. Table 1). Overall, the effect sizes in predicting AP
and GG 3−5 are comparable, CAPRA and Decipher alike
(e.g., Decipher Univariable-OR 1.36 for GG 3−5 vs. 1.34
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Fig. 1 Distribution of a CAPRA and b Decipher in the F-IR cohort (n = 220); c CAPRA and d Decipher in the combined cohort of VL/LR and FIR (n = 647). CAPRA Cancer of the Prostate Risk Assessment, VL/LR NCCN very low/low risk, F-IR NCCN favorable-intermediate risk

for AP) while the effect sizes in predicting AP-II are smaller
than the former two (e.g., Decipher Univariable-OR 1.22) as
we would expect from a boarder deﬁnition of adverse
pathology. The sensitivity analysis results in Supplementary
Table 2 demonstrated that our observations were robust to
institutional effect like local treatment preferences or
practices.

Table 3b). A bar graph illustrates the risk distributions of
the study cohort identiﬁed by three risk models (NCCN,
GC, and NCCN + GC combined). Corresponding AP rates
are annotated below each bar (Fig. 2). Rates of AP in the
combined model were low except for the small subset of
F-IR tumors with a high Decipher (GC > 0.6) score.

NCCN F-IR with Decipher low and intermediate risk
groups have same odds of AP as NCCN VL/LR tumors

Discussion

We next analyzed the 220 F-IR patients in comparison to
427 VL/LR tumors (Table 1, Fig. 1c, d). AP rate at RP in
the VL/LR tumors (n = 427) was 9% and was 11% overall
(n = 647). Overall, we found NCCN F-IR had increased
odds (OR 1.7, 95% CI 1.0−2.8, p < 0.05) of AP as compared to NCCN VL/LR tumors. When stratiﬁed by genomic
risk, only NCCN F-IR with a Decipher high-risk score (but
not those with low/intermediate) had a signiﬁcantly higher
odds for AP of 6.8 (p < 0.001) compared to VL/LR tumors
(Table 3). Decipher was consistently able to stratify further
NCCN F-IR tumors for the alternative AP endpoints as well
(Supplementary Table 3). As an example, for the AP-II
endpoint (which included any pT3 disease at RP) while
NCCN F-IR had an OR of 1.3 (95% CI 0.9−1.9, p = 0.1),
NCCN F-IR with a Decipher high-risk score had an OR of
3.8 (95% CI 1.5−10.4, p = 0.006) (Supplementary

The concept of classifying PCa patients by risk group is
now 20 years old [20], and while tremendous progress has
been made in the intervening decades in our understanding of PCa’s heterogeneous nature and subsequent,
complicated prognosis, risk groups are still endorsed by
the NCCN and other organizations [21]. Risk groups
overweight the importance of T-stage, inconsistently
consider the extent of biopsy involvement, do not consider multiple adverse parameters, and do not perform as
linear predictors [22]. The addition of the “very low-risk”
group and division of intermediate into “favorable” and
“unfavorable” has increased granularity, but at the cost of
much more complexity, and has not solved any of these
fundamental problems. Superior risk prediction using
continuous, linear, multivariable tools have been available
nearly as long as risk groups [23], and some have been
extensively validated [24]. The prognostic value of such
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Table 2 Firth’s penalized
logistic regression for Decipher
and CAPRA for AP in F-IR
cohort (n = 220)

A. Herlemann et al.
Model

Variable

Univariable

CAPRA + Decipher
CAPRA + Decipher
(risk group)

Odds ratio (95% CI) p value AUC (95% CI)

CAPRA

1.64 (1.03−2.68)

0.038*

0.60 (0.51−0.70)

Decipher

1.34 (1.11−1.63)

0.002*

0.63 (0.52−0.74)

Decipher int vs. low

0.85 (0.22−2.54)

0.789

—

Decipher high vs. low 4.60 (1.59−12.90)

0.006*

—

CAPRA

1.46 (0.91−2.39)

0.117

0.65 (0.57−0.71)a

Decipher

1.31 (1.08−1.60)

0.006*

CAPRA

1.78 (1.10−2.97)

0.018*

Decipher int vs. low

0.61 (0.15−1.91)

0.422

Decipher high vs. low 4.92 (1.65−14.41)

—

0.005*

Odds ratios of Decipher were reported per 0.1 unit increased
CAPRA Cancer of the Prostate Risk Assessment, AP adverse pathology, F-IR NCCN favorableintermediate risk
a

AUC was adjusted for optimism

*p value < 0.05

Table 3 Firth’s penalized
logistic regression for
stratiﬁcation of F-IR (n = 220)
by Decipher compared to VL/
LR (n = 427) predicting AP

Model

Variable

Odds ratio (95% CI) p value

NCCN

NCCN F-IR vs. VL/LR

1.71 (1.04−2.79)

NCCN stratiﬁed by Decipher NCCN F-IR + GC low vs. NCCN VL/LR 1.48 (0.85−2.53)
NCCN F-IR + GC int vs. NCCN VL/LR

1.26 (0.33−3.59)

NCCN F-IR + GC high vs. NCCN VL/LR 6.83 (2.45−18.31)

0.034*
0.160
0.700
<0.001*

F-IR NCCN favorable-intermediate risk, VL/LR NCCN very low/low risk, AP adverse pathology, NCCN
National Comprehensive Cancer Network, GC genomic classiﬁer–Decipher
*p value < 0.05

tools can be further improved by the incorporation of
genomic classiﬁers.
The NCCN prostate cancer guidelines now subdivide
men with intermediate-risk prostate cancer into favorable
and unfavorable intermediate-risk groups [6]. Recent studies have shown that men with unfavorable intermediateand high-risk features demonstrate similar mortality
outcomes [9]. Conversely, patients with F-IR tumors
demonstrate favorable survival rates and thus may qualify
for AS according to NCCN guidelines [8, 9]. However,
substantial heterogeneity still prevails within the F-IR
category. For example, CAPRA scores in the present F-IR
cohort vary from 0 to 4; most had scores of either 2 or 3—and
slight majority, mostly those with low—would be classiﬁed
as “low-risk” by CAPRA. In this study, we demonstrated
that among the F-IR tumors, only Decipher high-risk F-IR
tumors had increased odds of harboring AP. Moreover,
these ﬁndings were robust to the deﬁnition of AP used.
Appropriately selected AS patients have excellent longterm prostate cancer-speciﬁc survival rates [25]. Therefore,
some institutions have expanded the inclusion criteria for
AS to carefully selected “intermediate-risk” prostate cancer
patients to avoid potential overtreatment. However, observational data have shown that these men clearly are at
higher risk for upgrading, adverse pathology and

progression to metastatic disease [8, 26, 27]—ﬁndings that
we partly conﬁrmed in our analysis. Patel et al. [10]. aimed
in their comparative cohort study to subtype the risk of
patients with intermediate-risk prostate cancer for AS based
on adverse pathology at radical prostatectomy. They found
a threefold greater rate of adverse pathology among men
diagnosed with F-IR prostate cancer who underwent radical
prostatectomy relative to men at low-risk regardless of the
deﬁnition used [10]. Notably, the F-IR group also experienced worse survival rates compared to the men with lowrisk [10]. Given these results, the authors questioned if we
still should offer AS to intermediate-risk patients, even if
they show F-IR features.
For patients diagnosed with PCa and variable clinical
risk features, genomics classiﬁers may help overcome some
of the limitations of prostate biopsy and disease heterogeneity. One of the advantages of molecular proﬁling is to
assign risk based on an objective estimate of tumor biology,
independent of the skills of an individual pathologist [28].
Decipher is a validated genomic classiﬁer based on RNA
biomarkers related to cell proliferation and differentiation,
motility, immune modulation, and androgen receptor signaling. Recent studies have demonstrated substantial heterogeneity among histologically homogeneous VL/LR and
F-IR tumors [13, 28], and have shown that a small subset of
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Fig. 2 Proportion of combined cohort (n = 647) for each risk model
and AP rates. Bar heights represent proportions of patients being
identiﬁed by each risk grouping within a risk model; all three adverse
pathology rates are presented under each risk grouping; risk groupings
that are signiﬁcantly associated with AP are indicated by asterisks
followed by the AP rates (deﬁned using p value < 0.05 from univariable logistic regression models with reference groups either GC Low/
Int or NCCN VL/LR). GC Decipher, VL/LR NCCN very low/low risk,
F-IR NCCN favorable-intermediate risk

patients with GG1 tumors harbor biologically more
aggressive disease that may be more appropriately managed
by immediate deﬁnitive treatment. Interestingly, these studies have also demonstrated that signiﬁcant proportions of
“intermediate-risk” tumors have favorable molecular proﬁles, comparable to low-risk GG1 tumors, suggesting that
men with these “indolent” gene expression proﬁles may
qualify for AS [28].
We found that NCCN F-IR had increased odds (1.7 OR)
of adverse pathology as compared to NCCN VL/LR tumors,
which is consistent with previously reported data [10].
Importantly, however, in these same patients, the Decipher
score was a signiﬁcant predictor of adverse pathology.
When stratiﬁed by Decipher, we further showed that
patients with F-IR cancer with either a Decipher low or
intermediate risk group score did not have signiﬁcantly
higher odds of AP. Rather, only the small subset (3% in this
study) of F-IR patients with Decipher high-risk results had
increased risk of AP (OR of 6.8). Our data suggest that
integrating genomic classiﬁers into treatment decisionmaking may help identify the most suitable AS candidates
among patients with F-IR disease.
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Further options that may add value to AS patient selection include the use of multiparametric prostate magnetic
resonance imaging, given its high negative predictive value
for large high-grade cancers, and novel risk calculators that
may increase the number of intermediate-risk patients eligible for AS without increasing the risk of misclassiﬁcation
[29]. However, recent studies have demonstrated that
genomic classiﬁers are more accurate than MRI in predicting the presence of AP [30].
Limitations of this study include its retrospective nature and that certain pathologic features (such as LNI
alone, cribriform and intraductal histology, pT3a/pT3b or
higher alone) were not explored due to a low event rate.
AP is an imperfect endpoint; it is not rare for men to have
evidence of AP but to be cured with prostatectomy alone.
Due to low event rates and the lack of follow-up data in
GRID, oncologic endpoints such as biochemical recurrence, metastasis, and mortality were not evaluated, but
these endpoints must be the focus of future studies in the
F-IR group. It should be noted that Decipher has already
been extensively validated to predict these distal endpoints in higher risk cohorts [31, 32]. In the meantime, AP
does continue to drive clinical decision-making, particularly for men with lower clinical risk at diagnosis, and is
still the focus of ongoing biomarker studies. Additionally,
our patient cohort was derived from multiple centers
with varying approaches to workup and follow-up protocols and variable data collection; we do not, for example, have consistent access to PSA density, percent of
biopsy tissue involvement, cribriform histology, lymph
node count etc. We also do not have long-term PSA serial
data post-surgery on any of these men. Despite these
limitations, our data emphasize the beneﬁt and potential
role of genomic classiﬁers to better risk-stratify this speciﬁc patient population before ﬁnalizing treatment
decisions.

Conclusions
The NCCN risk group system has been modiﬁed to substratify intermediate risk patients as favorable and unfavorable to address some of its limitations, but these
subcategories are still highly heterogeneous clinically and
biologically. The Decipher biopsy test can accurately
identify patients within the NCCN F-IR group with higher
likelihood of AP at the time of RP. Men with NCCN F-IR
PCa and a low or intermediate Decipher score had similar
odds of AP as men with NCCN VL/LR PCa. Therefore,
incorporating Decipher into clinical decision-making, particularly for F-IR PCa, may be useful to safely expand the
use of active surveillance.
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